Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | WNT3A | P56704 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29270879 | 0.84 | KMT2A (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL26986446 | 0.82 | RAB9A (0.71) | KMT2AMEN1RAB9ANPC1PKM | |
| SCHEMBL4908980 | 0.81 | KMT2A (0.82) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL2815739 | 0.80 | KMT2A (0.63) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| Difenpiramide SCHEMBL23833 | 0.78 | KMT2A (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| Difenpiramide SCHEMBL29238669 | 0.78 | KMT2A (1.00) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL6490488 | 0.78 | KMT2A (0.74) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL3788722 | 0.75 | SMN1; SMN2 (0.74) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL4575591 | 0.75 | KMT2A (0.68) | KMT2AMEN1SLC6A2SLC6A3GAA | |
| SCHEMBL28194116 | 0.75 | KMT2A (0.68) | KMT2AMEN1SLC6A2SLC6A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024009232-A1 | SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| EP-2504338-B1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2315767-B1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-04 | — | — | EP | disclosed |
| US-8436011-B2 | Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-05-07 | — | — | US | disclosed |
| CN-102762558-A | Pyridopyridone derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2012-10-31 | — | — | CN | disclosed |
| EP-2504338-A1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20110124643-A1 | PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | US | disclosed |
| WO-2011061458-A1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | WO | disclosed |
| EP-2315767-A2 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010004197-A2 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124643-A1 | PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, PDGFRB, PDGFRA | KMT2A 2987/4885MEN1 2330/4885SLC6A2 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.